Pre-made Timolumab benchmark antibody ( Whole mAb, anti-AOC3 therapeutic antibody, Anti-HPAO/SSAO/VAP-1/VAP1 Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Timolumab biosimilar, Whole mAb, Anti-AOC3 Antibody: Anti-HPAO/SSAO/VAP-1/VAP1 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

TECHNOLOGY. DESCRIPTION. Timolumab (BTT-1023; SI-3106; SI-636) is a fully human, monoclonal, anti-vascular adhesion protein- 1 (VAP-1) antibody which works by blocking the adhesion function of VAP-1 which diminishes. leucocyte entry to sites of inflammation.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-577-1mg	1mg	3090
GMP-Bios-ab-577-10mg	10mg	Inquiry
GMP-Bios-ab-577-100mg	100mg	Inquiry
GMP-Bios-ab-577-xmg	＞100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Timolumab biosimilar, Whole mAb, Anti-AOC3 Antibody: Anti-HPAO/SSAO/VAP-1/VAP1 therapeutic antibody
INN Name	Timolumab
Target	AOC3
Format	Whole mAb
Derivation	Human
Species Reactivity	Human
CH1 Isotype	IgG4
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-II
Est. Status	Discontinued
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2015
Year Recommended	2016
Companies	Acorda Therapeutics;Biotie Therapies Corp.;Seikagaku Corporation
Conditions Approved	na
Conditions Active	na
Conditions Discontinued	Inflammation;Plaque psoriasis;Rheumatoid arthritis;Primary sclerosing cholangitis
Development Tech	na